Form 8-K - Current report:
SEC Accession No. 0001437749-24-027204
Filing Date
2024-08-19
Accepted
2024-08-19 16:10:01
Documents
16
Period of Report
2024-08-19
Items
Item 7.01: Regulation FD Disclosure
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 FORM 8-K mbrx20240819_8k.htm   iXBRL 8-K 28590
2 EXHIBIT 99.1 ex_716071.htm EX-99.1 14181
7 moleculin01.jpg GRAPHIC 8529
  Complete submission text file 0001437749-24-027204.txt   203279

Data Files

Seq Description Document Type Size
3 XBRL TAXONOMY EXTENSION SCHEMA mbrx-20240819.xsd EX-101.SCH 3409
4 XBRL TAXONOMY EXTENSION DEFINITION LINKBASE mbrx-20240819_def.xml EX-101.DEF 11424
5 XBRL TAXONOMY EXTENSION LABEL LINKBASE mbrx-20240819_lab.xml EX-101.LAB 15310
6 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE mbrx-20240819_pre.xml EX-101.PRE 11584
18 EXTRACTED XBRL INSTANCE DOCUMENT mbrx20240819_8k_htm.xml XML 2834
Mailing Address 5300 MEMORIAL DRIVE SUITE 950 HOUSTON TX 77007
Business Address 5300 MEMORIAL DRIVE SUITE 950 HOUSTON TX 77007 713-300-5160
Moleculin Biotech, Inc. (Filer) CIK: 0001659617 (see all company filings)

EIN.: 474671997 | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-37758 | Film No.: 241220525
SIC: 2834 Pharmaceutical Preparations
(CF Office: 03 Life Sciences)